[go: up one dir, main page]

EP1392294A4 - 7,8-CONDENSED 4 $ I (H) -CHROME AND ANALOGUE AS CASPASE ACTIVATORS AND APOLTOSIS DERIVATIVES AND THEIR USE - Google Patents

7,8-CONDENSED 4 $ I (H) -CHROME AND ANALOGUE AS CASPASE ACTIVATORS AND APOLTOSIS DERIVATIVES AND THEIR USE

Info

Publication number
EP1392294A4
EP1392294A4 EP02731801A EP02731801A EP1392294A4 EP 1392294 A4 EP1392294 A4 EP 1392294A4 EP 02731801 A EP02731801 A EP 02731801A EP 02731801 A EP02731801 A EP 02731801A EP 1392294 A4 EP1392294 A4 EP 1392294A4
Authority
EP
European Patent Office
Prior art keywords
apoltosis
chrome
analogue
condensed
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02731801A
Other languages
German (de)
French (fr)
Other versions
EP1392294A1 (en
Inventor
Sui Xiong Cai
Lifen Xu
Richard Storer
Giorgio Attardo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytovia Therapeutics LLC
Original Assignee
Cytovia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytovia Inc filed Critical Cytovia Inc
Publication of EP1392294A1 publication Critical patent/EP1392294A1/en
Publication of EP1392294A4 publication Critical patent/EP1392294A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP02731801A 2001-05-16 2002-05-16 7,8-CONDENSED 4 $ I (H) -CHROME AND ANALOGUE AS CASPASE ACTIVATORS AND APOLTOSIS DERIVATIVES AND THEIR USE Withdrawn EP1392294A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29097601P 2001-05-16 2001-05-16
US290976P 2001-05-16
PCT/US2002/015398 WO2002092083A1 (en) 2001-05-16 2002-05-16 7,8-fused 4$i(h)-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof

Publications (2)

Publication Number Publication Date
EP1392294A1 EP1392294A1 (en) 2004-03-03
EP1392294A4 true EP1392294A4 (en) 2006-05-17

Family

ID=23118291

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02731801A Withdrawn EP1392294A4 (en) 2001-05-16 2002-05-16 7,8-CONDENSED 4 $ I (H) -CHROME AND ANALOGUE AS CASPASE ACTIVATORS AND APOLTOSIS DERIVATIVES AND THEIR USE

Country Status (2)

Country Link
EP (1) EP1392294A4 (en)
WO (1) WO2002092083A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1230232E (en) 1999-11-05 2004-07-30 Cytovia Inc 4H-CROMENE AND ITS ANALOGS AS ACTIVATORS OF APOPTOSE CASPASES AND INDUCTORS AND THEIR UTILIZATION
US7476741B2 (en) 2002-05-16 2009-01-13 Cytovia, Inc. Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
JP2005531566A (en) 2002-05-16 2005-10-20 サイトビア インコーポレイティッド Substituted 4-aryl-4H-pyrrolo [2,3-H] chromenes and analogs and their use as caspase activators and apoptosis inducers
CA2522700A1 (en) 2003-04-18 2004-11-04 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
CN102924477B (en) * 2009-02-09 2014-10-29 沈阳药科大学 New oxazine compound and application thereof
EP2638025B1 (en) 2010-11-12 2020-02-05 Deutsches Krebsforschungszentrum (DKFZ) Chromene derivatives and their analoga as wnt pathway antagonists
CN107501281B (en) * 2017-09-26 2019-11-22 清华大学 Compound shown in formula I and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281619A (en) * 1992-09-25 1994-01-25 Eli Lilly And Company Therapy for diabetic complications
WO2001034591A2 (en) * 1999-11-05 2001-05-17 Cytovia, Inc. Substituted 4h-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9306062D0 (en) * 1993-03-24 1993-05-12 Lilly Industries Ltd Pharmaceutical compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281619A (en) * 1992-09-25 1994-01-25 Eli Lilly And Company Therapy for diabetic complications
WO2001034591A2 (en) * 1999-11-05 2001-05-17 Cytovia, Inc. Substituted 4h-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO02092083A1 *
WANG J-L ET AL: "STRUCTURE-BASED DISCOVERY OF AN ORGANIC COMPOUND THAT BINDS BCL-2 PROTEIN AND INDUCES APOPTOSIS OF TUMOR CELLS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 97, no. 13, 20 June 2000 (2000-06-20), pages 7124 - 7129, XP001061264, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
EP1392294A1 (en) 2004-03-03
WO2002092083A1 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
ATE332294T1 (en) DIHYDRO-1,3,5-TRIAZINE-DIAMINE DERIVATIVES AND THEIR THERAPEUTIC USE
DE60234376D1 (en) 3-BETA-D-RIBOFURANOSYLTHIAZOLO (4,5-DELTA) PYRIDIMINE NUCLEOSIDE AND ITS USE
DE60036803D1 (en) ARYLMETHYL-CARBONYLAMINO-THIAZONE DERIVATIVES AND THEIR USE AS ANTITUM-MEANS
DE60127997D1 (en) 1,5-BENZOTHIAZEPINE AND ITS USE AS ANTI-HYPERLIPIDÄMIKA
DE60139401D1 (en) ENLARGEMENT OF THE AREA OF COMPUTER BODIES OF ALL NUMBERS
ATE232865T1 (en) 1,4-DIAZABICYCLO(3.2.2)NONAN-4-CARBOXYLATE AND CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE
DE69929983D1 (en) TRIFLUOROMETHYLPYROCARBOXAMIDES AND THEIR USE AS FUNGICIDES
DE69840599D1 (en) ANTIMICROBIAL CHINOLONE, ITS COMPOSITIONS, AND ITS USES
DE60127233D1 (en) 4-AMINOPICOLINATE AND ITS USE AS HERBICIDES
EP1021185A4 (en) DIHYDROPYRIMIDINE AND ITS USES.
DE50213336D1 (en) SUBSTITUTED 2-THIO-3,5-DICYANO-4-PHENYL-6-AMINOPYRIDINE AND ITS USE
ATE277895T1 (en) 4-BROMINE OR 4-IODINE-PHENYLAMINO-BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS
DE69911786D1 (en) AIR-DRIVEN PUMPS AND ITS COMPONENTS
DE60002696D1 (en) ELIMINATION OF REDUNDANCY IN THE PERSISTENCE OF OBJECT GRAPHS
DE50207849D1 (en) SUBSTITUTED 2-OXY-3,5-DICYANO-4-ARYL-6-AMINOPYRIDINE AND ITS USE
DE69836346D1 (en) HETEROARYL AMINOGUANIDIN AND ALKOXYGUANIDINE DERIVATIVES AND THEIR USE AS PROTEASE INHIBITORS
DE60209486D1 (en) PYRANOINDAZOLE AND ITS USE IN GLUCKOM TREATMENT
DE60016326D1 (en) Water-absorbent composition and its use
DE60216275D1 (en) USE OF AZETIDINONE-SUBSTITUTED DERIVATIVES IN THE TREATMENT OF ALZHEIMER DISEASE
ATE320256T1 (en) SUCCINATES OF 5,8,14-TRIAZATETRACYCLO(10.3.1.0 2, 11 .0 4,9 )-HEXADECA-2(11),3,5,7,9,-PENTAENE AND PHARMACEUTICAL COMPOSITIONS
ATE420642T1 (en) NEW FORMULATIONS AND THEIR USE
ATE426603T1 (en) ACYL AND SULFONYL DERIVATIVES 6,9-DISUBSTITUTED 2-(TRANS-1,4-DIAMINOCYCLOHEXYL)-PURINES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS
DE60103394D1 (en) 4- (2-PHENYLTHIAZOL-5-YL) 1,4-DIAZABICYCLO [3.2.2] NONAN DERIVATIVES, THEIR MANUFACTURE AND THERAPEUTIC USES
DE60313895D1 (en) 2,7-DISUBSTITUTED USES AND THEIR USE AS 5-HT6 MODULATORS
ATE265454T1 (en) PHENYLOXAZOLE-1,4-DIAZABICYCLO(3.2.2)NONANDERIVA E, ITS PRODUCTION AND THEIR THERAPEUTIC USE

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031202

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CYTOVIA, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20060331

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20070403